[1]
|
NUCLEOTIDE SEQUENCE [MRNA].
DOI=10.1016/0003-9861(92)90152-M; PubMed=1550342 [NCBI, ExPASy, EBI, Israel, Japan]
Shephard E.A.,
Palmer C.N.,
Segall H.J.,
Phillips I.R.;
"Quantification of cytochrome P450 reductase gene expression in human tissues.";
Arch. Biochem. Biophys. 294:168-172(1992).
|
[2]
|
NUCLEOTIDE SEQUENCE [MRNA].
TISSUE=Liver;
Czerwinski M.,
Sahni M.,
Madan A.,
Parkinson A.;
"Polymorphism of human CYPOR: expression of new allele.";
Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
|
[3]
|
NUCLEOTIDE SEQUENCE [MRNA].
Murakami H.O.,
Ogawa H.,
Nisimoto Y.;
"cDNA cloning and characterization of NADPH-cytochrome P-450 reductase in human HL-60 cell.";
Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
|
[4]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-500.
TISSUE=Lung;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
|
[5]
|
PROTEIN SEQUENCE OF 2-677.
TISSUE=Liver;
DOI=10.1021/bi00447a054; PubMed=2513880 [NCBI, ExPASy, EBI, Israel, Japan]
Haniu M.,
McManus M.E.,
Birkett D.J.,
Lee T.D.,
Shively J.E.;
"Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites.";
Biochemistry 28:8639-8645(1989).
|
[6]
|
X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 62-242.
PubMed=10048323 [NCBI, ExPASy, EBI, Israel, Japan]
Zhao Q.,
Modi S.,
Smith G.,
Paine M.,
McDonagh P.D.,
Wolf C.R.,
Tew D.,
Lian L.Y.,
Roberts G.C.,
Driessen H.P.;
"Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution.";
Protein Sci. 8:298-306(1999).
|
[7]
|
VARIANT AHV HIS-454.
DOI=10.1002/ajmg.a.30169; PubMed=15264278 [NCBI, ExPASy, EBI, Israel, Japan]
Adachi M.,
Tachibana K.,
Asakura Y.,
Yamamoto T.,
Hanaki K.,
Oka A.;
"Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome.";
Am. J. Med. Genet. A 128:333-339(2004).
|
[8]
|
VARIANTS AHV HIS-454; CYS-575 AND 608-LEU--TRP-617 DELINS ARG, AND VARIANT VAL-500.
DOI=10.1210/jc.2004-0810; PubMed=15483095 [NCBI, ExPASy, EBI, Israel, Japan]
Fukami M.,
Horikawa R.,
Nagai T.,
Tanaka T.,
Naiki Y.,
Sato N.,
Okuyama T.,
Nakai H.,
Soneda S.,
Tachibana K.,
Matsuo N.,
Sato S.,
Homma K.,
Nishimura G.,
Hasegawa T.,
Ogata T.;
"Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.";
J. Clin. Endocrinol. Metab. 90:414-426(2005).
|
[9]
|
VARIANTS AHV ASP-178; PRO-284; HIS-454 AND TYR-566, AND CHARACTERIZATION OF VARIANTS AHV ASP-178; PRO-284; HIS-454 AND TYR-566.
DOI=10.1016/S0140-6736(04)16503-3; PubMed=15220035 [NCBI, ExPASy, EBI, Israel, Japan]
Arlt W.,
Walker E.A.,
Draper N.,
Ivison H.E.,
Ride J.P.,
Hammer F.,
Chalder S.M.,
Borucka-Mankiewicz M.,
Hauffa B.P.,
Malunowicz E.M.,
Stewart P.M.,
Shackleton C.H.L.;
"Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.";
Lancet 363:2128-2135(2004).
|
[10]
|
VARIANTS AHV PRO-284; HIS-454 AND GLU-489, VARIANTS IDS TYR-566 AND PHE-605, CHARACTERIZATION OF VARIANTS AHV PRO-284; HIS-454 AND GLU-489, AND CHARACTERIZATION OF VARIANTS IDS TYR-566 AND PHE-605.
DOI=10.1038/ng1300; PubMed=14758361 [NCBI, ExPASy, EBI, Israel, Japan]
Flueck C.E.,
Tajima T.,
Pandey A.V.,
Arlt W.,
Okuhara K.,
Verge C.F.,
Jabs E.W.,
Mendonca B.B.,
Fujieda K.,
Miller W.L.;
"Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.";
Nat. Genet. 36:228-230(2004).
|
|
ExPASy Home page
YPRC Korea
